US · VRCA
Verrica Pharmaceuticals Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- West Chester, PA 19380
- Website
- verrica.com
Price · as of 2024-12-31
$6.27
Market cap 51.91M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $10.96 | +74.8% |
| Intrinsic Value(DCF) | $2.43 | -61.24% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $109.80 | ||||
| 2019 | $119.60 | ||||
| 2020 | $169.30 | ||||
| 2021 | $78.80 | ||||
| 2022 | $65.60 | $136.99 | $7.14 | $0.00 | $111.75 |
| 2023 | $50.10 | $43.00 | $0.00 | $0.00 | $490.41 |
| 2024 | $6.08 | $10.96 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Verrica Pharmaceuticals Inc.'s (VRCA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $10.96
- Current price
- $6.27
- AI upside
- +74.8%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.43
-61.24% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VRCA | Verrica Pharmaceuticals I… | $6.27 | 51.91M | +75% | -61% | — | — | -0.41 | -3.19 | 4.16 | -0.47 | — | -3.19 | 63.79% | -871.25% | -1012.15% | -1546.58% | 907.73% | -112.84% | -4.66 | -7.00 | 1.76 | 1.60 | 0.01 | 0.00% | 4766.00% | 5654.00% | -193.51% | -2.10 | 839.36% | 0.00% | 0.00% | 0.00% | -0.47 | -0.51 | 4.11 | -11.03 |
| ANTX | AN2 Therapeutics, Inc. | $1.10 | 30.14M | — | — | — | — | -0.76 | 0.48 | — | -13.78 | — | 0.48 | 0.00% | — | — | -49.69% | -697.76% | -44.47% | 0.00 | — | 8.43 | 8.20 | -6.60 | -3723.00% | — | -756.00% | -126.06% | -4.81 | -630.01% | 0.00% | 0.00% | 14.60% | 0.82 | 0.90 | — | -1.80 |
| BOLD | Boundless Bio, Inc. | $1.16 | 25.97M | — | — | — | — | -0.44 | 0.19 | — | 1.18 | -0.60 | 0.19 | 0.00% | — | — | -554.86% | 73.46% | -38.87% | 0.32 | — | 18.98 | 18.70 | -0.33 | 7342.00% | — | 3346.00% | -220.80% | -7.48 | 63.54% | 0.00% | 0.00% | 0.00% | 1.03 | 1.20 | — | -1.38 |
| EVAX | Evaxion Biotech A/S | $3.16 | 19.96M | +25,906% | -76% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| GBIO | Generation Bio Co. | $5.34 | 35.98M | +46% | -60% | — | — | -0.27 | 0.41 | 1.78 | 0.76 | -40.69 | 0.41 | 100.00% | -715.82% | -661.91% | -91.02% | -912.79% | -43.46% | 1.09 | — | 5.50 | 5.33 | -0.23 | 66.00% | 23692.00% | 5125.00% | -256.40% | -2.53 | -583.12% | 0.00% | 0.00% | 39.99% | 0.39 | 0.62 | -2.82 | -5.24 |
| JSPR | Jasper Therapeutics, Inc. | $1.38 | 22.43M | — | — | — | — | -1.10 | 1.27 | — | -0.11 | — | 1.27 | 0.00% | — | — | -101.73% | 1104.03% | -81.55% | 0.03 | — | 4.98 | 4.70 | 0.93 | -2087.00% | — | 2067.00% | -80.64% | -4.11 | 914.55% | 0.00% | 0.00% | 0.00% | -0.11 | -0.13 | — | -3.88 |
| MURA | Mural Oncology plc | $2.04 | 35.38M | — | — | — | — | -0.48 | 0.44 | — | 0.60 | — | 0.44 | 0.00% | — | — | -63.57% | -2282.87% | -54.55% | 0.06 | — | 5.84 | 5.51 | 0.86 | -3902.00% | — | -3493.00% | -209.58% | -4.91 | -2123.95% | 0.00% | 0.00% | 0.00% | 0.54 | 0.58 | — | -1.84 |
| NXTC | NextCure, Inc. | $12.72 | 34.09M | — | — | — | — | -0.38 | 0.32 | — | 0.77 | — | 0.32 | 0.00% | — | — | -61.87% | -769.60% | -53.28% | 0.09 | — | 7.50 | 7.20 | 0.40 | -1168.00% | — | -2326.00% | -196.82% | -4.26 | -531.71% | 0.00% | 0.00% | 72.95% | 0.70 | 1.01 | — | -7.28 |
| PSTV | Plus Therapeutics, Inc. | $0.30 | 18.31M | +20,855% | +1,192% | — | — | -0.80 | -1.16 | 1.79 | -1.21 | — | -1.06 | 85.37% | -252.32% | -222.84% | 252.07% | 197.13% | -144.03% | -0.38 | -3.95 | 0.34 | 0.27 | -0.39 | -4481.00% | 1854.00% | -1776.00% | -102.64% | -0.68 | 143.54% | 0.00% | 0.00% | 3.59% | -0.69 | -0.95 | 1.75 | -112.05 |
| QTTB | Q32 Bio Inc. | $4.56 | 56.11M | +726% | — | — | — | -0.57 | 4.77 | — | 0.71 | — | 4.77 | 0.00% | — | — | 53.86% | 62.63% | -68.49% | 3.33 | -220.34 | 4.97 | 4.77 | 1.30 | -6060.00% | -10000.00% | 26286.00% | -250.34% | -4.11 | 64.23% | 0.00% | 0.00% | 311.27% | 0.48 | 0.47 | — | -4.89 |
| SABS | SAB Biotherapeutics, Inc. | $4.10 | 39.19M | +213% | -84% | — | +2,692% | -0.44 | 0.58 | 11.35 | 0.04 | — | 0.58 | -262.41% | -3244.87% | -2579.03% | -81.92% | -519.55% | -53.23% | 0.18 | -134.77 | 2.98 | 2.61 | 0.15 | -5183.00% | -4094.00% | 3679.00% | -230.79% | -4.30 | -419.29% | 0.00% | 0.00% | 0.00% | 0.03 | 0.03 | -0.82 | -6.18 |
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
- CEO
- Jayson Rieger
- Employees
- 71
- Beta
- 1.44
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.43 ÷ $6.27) − 1 = -61.24% (DCF, example).